| Valuation method | Value, € | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 23.10 | 362 |
| Intrinsic value (DCF) | 1.14 | -77 |
| Graham-Dodd Method | n/a | |
| Graham Formula | 21.52 | 330 |
Inventiva S.A. (IVA.PA) is a clinical-stage biopharmaceutical company headquartered in Daix, France, specializing in the development of oral small molecule therapies for serious diseases. The company's primary focus is on non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other conditions with high unmet medical needs. Its lead candidate, Lanifibranor, has completed Phase IIb trials for NASH, a progressive liver disease with no currently approved treatments. Inventiva also develops Odiparcil for MPS VI and maintains an early-stage pipeline in oncology. The company has strategic collaborations with AbbVie for autoimmune diseases and Boehringer Ingelheim for idiopathic pulmonary fibrosis. Operating in the high-growth biotechnology sector, Inventiva leverages its expertise in nuclear receptor and fibrosis biology to address complex diseases. With a market cap of approximately €382 million, the company represents a specialized investment opportunity in European biotech innovation.
Inventiva presents a high-risk, high-reward investment profile typical of clinical-stage biotechs. The company's valuation hinges on the success of Lanifibranor in NASH, a potentially massive market with projected peak sales exceeding $20 billion globally. While the Phase IIb data showed promise, investors must weigh the significant cash burn (€184.2M net loss in 2024) against the long development timelines and regulatory risks inherent in NASH drug development. The AbbVie and Boehringer partnerships provide validation but limited near-term revenue. With €96.6M in cash and substantial R&D expenses, the company may require additional financing. The stock's beta of 0.97 suggests moderate volatility relative to the market. Suitable only for investors comfortable with binary clinical trial outcomes and long development cycles.
Inventiva competes in the intensely competitive NASH therapeutics space, where numerous large-cap pharma and biotech firms are pursuing multiple mechanisms. The company's competitive edge lies in Lanifibranor's pan-PPAR agonist approach, which showed favorable histologic improvement and safety in Phase IIb versus competing PPAR-targeting drugs that often face tolerability issues. However, the NASH field remains highly risky after several late-stage failures from competitors. Inventiva's small size allows agility but limits resources compared to deep-pocketed rivals. Its MPS program faces less competition but targets a smaller market. The AbbVie collaboration provides credibility but doesn't guarantee commercial success. Inventiva's French base gives access to European research networks but may limit U.S. market familiarity. The company's technology platform shows promise across multiple indications, potentially creating value beyond lead candidates. Success will depend on demonstrating differentiated efficacy/safety profiles and securing strategic partnerships for late-stage development and commercialization.